Literature DB >> 11578390

The efficacy of postoperative vaginal irradiation in preventing vaginal recurrence in endometrial cancer.

P. Elliott1, D. Green, A. Coates, M. Krieger, P. Russell, M. Coppleson, J. Solomon, M. Tattersall.   

Abstract

Between 1960 and 1985 hysterectomy was performed on 811 FIGO stage I and 116 stage II endometrial cancers which were divided into three groups: low-risk stage Ii (grade 1 and 2 lesions confined to the inner third of the myometrium; high-risk stage Iii (grade 3 and/or invading to the middle third of the myometrium or beyond); and FIGO stage II tumors (also high-risk). Hysterectomy was the only treatment in 492; in 145 the vaginal vault alone was radiated and in 290 the whole vagina, in each instance by an intracavity dose of 60Gy; in 34 of the latter high-risk tumors the pelvis received an additional 46Gy by external beam therapy. Forty isolated vaginal recurrences were detected; 10 in 308 low-risk and 22 in 184 high-risk tumors treated by surgery alone, and two and five in 40 low and 105 high-risk patients, respectively, who received adjuvant vault irradiation. No recurrences followed irradiation of the whole vaginal mucosa in 163 stage Ii low-risk and 40 stage II lesions and one, 9 years later, in 87 high-risk stage Iii tumors. Nearly 45% of patients with vaginal recurrence died from cancer within 1 year, 77% within 5 years and only 10% survived their recurrence 10 years. Total vaginal irradiation eliminated vaginal recurrences in low risk and reduced the incidence to 2.1% at 20 years after high-risk tumors.

Entities:  

Year:  1994        PMID: 11578390     DOI: 10.1046/j.1525-1438.1994.04020084.x

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  7 in total

1.  Concomitant postoperative radiation and chemotherapy following surgery was associated with improved overall survival in patients with FIGO stages III and IV endometrial cancer.

Authors:  Kentaro Nakayama; Yutaka Nagai; Masako Ishikawa; Yoichi Aoki; Khoji Miyazaki
Journal:  Int J Clin Oncol       Date:  2010-04-24       Impact factor: 3.402

2.  Survival Outcomes Improved in Contemporary Cohort of Patients With Pelvic or Abdominal Recurrence After Treatment for Stage I/II Endometrial Carcinoma.

Authors:  Melody J Xu; Christina Chu; Stephen Rubin; Lilie L Lin
Journal:  Am J Clin Oncol       Date:  2017-12       Impact factor: 2.339

3.  Three or four fractions per week in postoperative high-dose-rate brachytherapy for endometrial carcinoma. The long-term results on vaginal relapses and toxicity.

Authors:  I Valduvieco; Á Rovirosa; A Herreros; I Romera; I Ríos; C Ascaso; A Sánchez-Reyes; M Arenas; J Pahisa; A Biete
Journal:  Clin Transl Oncol       Date:  2012-12-21       Impact factor: 3.405

Review 4.  Typical and atypical metastatic sites of recurrent endometrial carcinoma.

Authors:  Vikram Kurra; Katherine M Krajewski; Jyothi Jagannathan; Angela Giardino; Suzanne Berlin; Nikhil Ramaiya
Journal:  Cancer Imaging       Date:  2013-03-26       Impact factor: 3.909

5.  Treatment outcomes and prognostic factors in mexican patients with endometrial carcinoma with emphasis on patients receiving radiotherapy after surgery: an institutional perspective.

Authors:  Christian Flores; Carlos Mariscal; Alfredo Celis; Nidia M Balcázar; Abelardo Meneses; Alejandro Mohar; Aida Mota; Elizabeth Trejo
Journal:  ISRN Oncol       Date:  2012-05-17

6.  Paclitaxel and concomitant radiotherapy in high-risk endometrial cancer patients: preliminary findings.

Authors:  Giorgia Mangili; Patrizia De Marzi; Saverio Beatrice; Emanuela Rabaiotti; Riccardo Viganò; Luigi Frigerio; Cinzia Gentile; Ferruccio Fazio
Journal:  BMC Cancer       Date:  2006-07-25       Impact factor: 4.430

7.  Factors associated with survival after relapse in patients with low-risk endometrial cancer treated with surgery alone.

Authors:  Nazli Topfedaisi Ozkan; Mehmet Mutlu Meydanlı; Mustafa Erkan Sarı; Fuat Demirkiran; Ilker Kahramanoglu; Tugan Bese; Macit Arvas; Hanifi Şahin; Ali Haberal; Husnu Celik; Gonca Coban; Tufan Oge; Omer Tarik Yalcin; Özgür Akbayır; Baki Erdem; Ceyhun Numanoğlu; Nejat Özgül; Gökhan Boyraz; Mehmet Coşkun Salman; Kunter Yüce; Murat Dede; Mufit Cemal Yenen; Salih Taşkın; Duygu Altın; Uğur Fırat Ortaç; Hülya Aydın Ayık; Tayup Şimşek; Tayfun Güngör; Kemal Güngördük; Muzaffer Sancı; Ali Ayhan
Journal:  J Gynecol Oncol       Date:  2017-06-16       Impact factor: 4.401

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.